Cargando…

SLC31A1 Identifying a Novel Biomarker with Potential Prognostic and Immunotherapeutic Potential in Pan-Cancer

Solute carrier family 31 member 1 (SLC31A1) encodes a protein that functions as a homotrimer for the uptake of dietary copper. As a vital member of the cuproptosis gene family, it plays an essential role in both normal tissues and tumors. In this study, we analyzed SLC31A1 across human cancer types...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Pei, Yang, Heqi, Zhu, Kaiguo, Chang, Chen, Lv, Wanrui, Li, Ruizhen, Li, Xiaoying, Ye, Tinghong, Cao, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669416/
https://www.ncbi.nlm.nih.gov/pubmed/38001885
http://dx.doi.org/10.3390/biomedicines11112884
_version_ 1785139691414093824
author Zhang, Pei
Yang, Heqi
Zhu, Kaiguo
Chang, Chen
Lv, Wanrui
Li, Ruizhen
Li, Xiaoying
Ye, Tinghong
Cao, Dan
author_facet Zhang, Pei
Yang, Heqi
Zhu, Kaiguo
Chang, Chen
Lv, Wanrui
Li, Ruizhen
Li, Xiaoying
Ye, Tinghong
Cao, Dan
author_sort Zhang, Pei
collection PubMed
description Solute carrier family 31 member 1 (SLC31A1) encodes a protein that functions as a homotrimer for the uptake of dietary copper. As a vital member of the cuproptosis gene family, it plays an essential role in both normal tissues and tumors. In this study, we analyzed SLC31A1 across human cancer types to gain a better understanding of SLC31A1’s role in cancer development. We searched for information using online databases to analyze, systematically and comprehensively, the role of SLC31A1 in tumors. Amongst nine cancer types, the expression of SLC31A1 was significantly different between tumors and normal tissues. According to further analysis, pancreatic cancer had the highest mutation rate of the SLC31A1 gene, and the methylation levels of the gene were significantly reduced in seven tumors. The expression of SLC31A1 is also linked to the infiltration of tumors by immune cells, the expression of immune checkpoint genes, and immunotherapy markers (TMB and MSI), suggesting that SLC31A1 may be of particular relevance in immunotherapy. This thorough analysis of SLC31A1 across different types of cancer gives us a clear and comprehensive insight into its role in causing cancer on a systemic level.
format Online
Article
Text
id pubmed-10669416
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106694162023-10-25 SLC31A1 Identifying a Novel Biomarker with Potential Prognostic and Immunotherapeutic Potential in Pan-Cancer Zhang, Pei Yang, Heqi Zhu, Kaiguo Chang, Chen Lv, Wanrui Li, Ruizhen Li, Xiaoying Ye, Tinghong Cao, Dan Biomedicines Article Solute carrier family 31 member 1 (SLC31A1) encodes a protein that functions as a homotrimer for the uptake of dietary copper. As a vital member of the cuproptosis gene family, it plays an essential role in both normal tissues and tumors. In this study, we analyzed SLC31A1 across human cancer types to gain a better understanding of SLC31A1’s role in cancer development. We searched for information using online databases to analyze, systematically and comprehensively, the role of SLC31A1 in tumors. Amongst nine cancer types, the expression of SLC31A1 was significantly different between tumors and normal tissues. According to further analysis, pancreatic cancer had the highest mutation rate of the SLC31A1 gene, and the methylation levels of the gene were significantly reduced in seven tumors. The expression of SLC31A1 is also linked to the infiltration of tumors by immune cells, the expression of immune checkpoint genes, and immunotherapy markers (TMB and MSI), suggesting that SLC31A1 may be of particular relevance in immunotherapy. This thorough analysis of SLC31A1 across different types of cancer gives us a clear and comprehensive insight into its role in causing cancer on a systemic level. MDPI 2023-10-25 /pmc/articles/PMC10669416/ /pubmed/38001885 http://dx.doi.org/10.3390/biomedicines11112884 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zhang, Pei
Yang, Heqi
Zhu, Kaiguo
Chang, Chen
Lv, Wanrui
Li, Ruizhen
Li, Xiaoying
Ye, Tinghong
Cao, Dan
SLC31A1 Identifying a Novel Biomarker with Potential Prognostic and Immunotherapeutic Potential in Pan-Cancer
title SLC31A1 Identifying a Novel Biomarker with Potential Prognostic and Immunotherapeutic Potential in Pan-Cancer
title_full SLC31A1 Identifying a Novel Biomarker with Potential Prognostic and Immunotherapeutic Potential in Pan-Cancer
title_fullStr SLC31A1 Identifying a Novel Biomarker with Potential Prognostic and Immunotherapeutic Potential in Pan-Cancer
title_full_unstemmed SLC31A1 Identifying a Novel Biomarker with Potential Prognostic and Immunotherapeutic Potential in Pan-Cancer
title_short SLC31A1 Identifying a Novel Biomarker with Potential Prognostic and Immunotherapeutic Potential in Pan-Cancer
title_sort slc31a1 identifying a novel biomarker with potential prognostic and immunotherapeutic potential in pan-cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669416/
https://www.ncbi.nlm.nih.gov/pubmed/38001885
http://dx.doi.org/10.3390/biomedicines11112884
work_keys_str_mv AT zhangpei slc31a1identifyinganovelbiomarkerwithpotentialprognosticandimmunotherapeuticpotentialinpancancer
AT yangheqi slc31a1identifyinganovelbiomarkerwithpotentialprognosticandimmunotherapeuticpotentialinpancancer
AT zhukaiguo slc31a1identifyinganovelbiomarkerwithpotentialprognosticandimmunotherapeuticpotentialinpancancer
AT changchen slc31a1identifyinganovelbiomarkerwithpotentialprognosticandimmunotherapeuticpotentialinpancancer
AT lvwanrui slc31a1identifyinganovelbiomarkerwithpotentialprognosticandimmunotherapeuticpotentialinpancancer
AT liruizhen slc31a1identifyinganovelbiomarkerwithpotentialprognosticandimmunotherapeuticpotentialinpancancer
AT lixiaoying slc31a1identifyinganovelbiomarkerwithpotentialprognosticandimmunotherapeuticpotentialinpancancer
AT yetinghong slc31a1identifyinganovelbiomarkerwithpotentialprognosticandimmunotherapeuticpotentialinpancancer
AT caodan slc31a1identifyinganovelbiomarkerwithpotentialprognosticandimmunotherapeuticpotentialinpancancer